Navigation Links
BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
Date:1/10/2008

pect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection may not be correct, that DHHS and the FDA may not agree with our analysis, that DHHS may further condition, reduce or eliminate future funding of the peramivir program, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in CTCL may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient c
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. Medpace Strengthens Presence in Central Europe
5. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
6. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
7. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
8. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
9. Anavex strengthens Board of Directors
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important ... patients with metastatic renal cancer at the ASCO Genitourinary ... The data will be presented by Dr. Sumanta ... Center in California in his ... Ferritin and IL-8 as two baseline biomarkers that correlate ...
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/27/2015)... BERKELEY, Calif. , Feb. 27, 2015  Steep ... in the US and internationally, intends to open a ... Albuquerque, New Mexico , bringing advanced scientific ... of cannabis. Steep Hill is currently the ... Health to conduct potency and contaminant testing in order ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
... In this month,s special issue of Physics World, which examines ... Kinsler of Imperial College London describe a new type of ... events. Using the ultimate bank heist as an example, ... use an "event cloak" to steal money from a safe, ...
... looked like when it was a baby. They know what ... it looked in its youth. Thanks to technological advances, however, ... picture of how the cosmos developed into the kind of ... They plan to gather these never-before-obtained insights with a ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... on-label use of PROVENGE® (sipuleucel-T), the first autologous ... minimally symptomatic metastatic castrate resistant (hormone refractory) prostate ... U.S. Food and Drug Administration (FDA) approved the ...
Cached Biology Technology:Why 'event cloaks' could be the key to the ultimate bank heist 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 3Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 4Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 2Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 3Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 4
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... CHAMPAIGN, lll. Blood clotting is a complicated business, ... to injury. In a new study, researchers report that they ... interaction that is vital to blood clotting. This interaction ... baffled scientists for decades. The study appears ...
... Research from North Carolina State University shows that ... good in landfills, because they are releasing a powerful ... such as disposable cups and utensils, are broken down ... Dr. Morton Barlaz, co-author of a paper describing the ...
... lightweight web service interface for accessing massive amounts ... and private domains has been developed by researchers ... powerful RIKEN Scientists, Networking System (SciNetS), the service ... to millions of data records and their network ...
Cached Biology News:Team solves decades-old molecular mystery linked to blood clotting 2Team solves decades-old molecular mystery linked to blood clotting 3Study: Biodegradable products may be bad for the environment 2Web interface defines new paradigm for life science data-sharing 2
Request Info...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Request Info...
Request Info...
Biology Products: